Jane Street’s Grace Therapeutics GRCE Stock Holding History

Jane Street’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Buy	+72,100	New	+$199K	﹤0.01%	10280

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street's GRCE Position: Q2 2026 in Review

Jane Street reduced its Grace Therapeutics (GRCE) stake by 46% in Q2 2026, selling an estimated $215K and leaving 89,442 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #10101.

Jane Street first reported a position in GRCE in Q2 2014 and has held it in 9 quarters since. The position peaked at $774K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Jane Street held 89,442 shares of Grace Therapeutics worth $203K as of Q2 2026.
Jane Street sold 77,655 Grace Therapeutics shares in Q2 2026, an estimated $215K.
Grace Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10101 holding.
Jane Street first reported a position in Grace Therapeutics in Q2 2014 and has held it in 9 quarters since.
Jane Street's Grace Therapeutics position peaked at $774K in Q1 2026.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.